Vitiligo during Treatment of Crohn's Disease with Adalimumab: Adverse Effect or Co-Occurrence
Adalimumab is a fully human monoclonal anti-tumor necrosis factor-α agent that is approved for the treatment of Crohn's disease. It has a good safety profile, injection site reactions being the most common adverse effect. We report a case of a 54-year-old woman with a 30-year history of Crohn&#...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Karger Publishers,
2011-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |